Presentations and Interviews

Erik Penser – Interview with CSO Johan Sandin about AlzeCure’s projects.

Interview at Finwire news with CEO Martin Jönsson (The presentation will be held in Swedish).

Rights Issue presentation with CEO Martin Jönsson at Erik Penser Bank.

Erik Penser – Interview with Martin Jönsson about the ongoing Rights Issue.

CEO Martin Jönsson presents AlzeCure at BioStock.

AlzeCure’s CEO Martin Jönsson presents at BioStock in connection with a new share issue, December 5, 2022.

Preclinical characterization of ACD856. Scientific presentation at the CTAD conference nov 29- 2dec, 2022.

AC-0027875, a novel gamma-secretase modulator. Scientific presentation at the CTAD conference nov 29- 2dec, 2022.

Quantitative EEG results from a multiple ascending dose study. Scientific presentation at the CTAD conference nov 29- 2dec, 2022.

CEO Martin Jönsson interviewed at Redeye Life Sciences Day on the company’s positive development & plans, as well as about the proposed rights issue in December and the positive progress in the Alzheimer’s market, and what this means for AlzeCure.

Martin Jönsson presented at Life Science Investor Conference the company’s successes and ongoing projects, as well as the company’s new share issue.

CEO Martin Jönsson presents AlzeCure’s progress and ongoing projects, as well as the company’s proposed share issue. (English)

Aktiespararna’s event with AlzeCure on November 16, 2022 – Martin Jönsson, AlzeCure’s CEO, presented the company’s progress and ongoing projects, as well as the company’s planned share issue. The presentation was held in Swedish.

CEO Martin Jönsson presented the company’s latest developments at Redeye Theme: Neurology on October 12, 2022.

CEO Martin Jönsson presented an update on our Pain management projects at Redeye Theme: Neurology on October 12.

The Trk-PAM ACD856 improves mitochondrial function and increases BDNF levels in primary cortical neurons; Scientific presentation at the ISMND Conference, Athens, October 10-12, 2022.

Analgesic and Anti-inflammatory Effects of Small Molecule Negative Allosteric Modulators of TrkA; Scientific presentation at the IASP Conference, Toronto, September 19-23, 2022.

Martin talks about the latest developments for AlzeCure including the phase 2 study with ACD 440 against neuropathic pain, the new positive clinical results with NeuroRestore ACD 856, our new patent and the new results with the pain project TrkA-NAM. (Swedish).

Interview with CEO Martin Jönsson and CSO Johan Sandin at Redeye about the latest clinical progress (Swedish).

Results From a Multiple Ascending Dose Study in Healthy Volunteers of ACD856, a Positive Modulator of Neurotrophin Trk-Receptors AAIC July – Aug 2022.

Watch the interview with Aktiespararna at Finwire with AlzeCure’s CEO Martin Jönsson. (Swedish).

AlzeCure – Interview at Redeye with CEO Martin Jönsson about the phase II study with ACD440. (Swedish).

AlzeCure at Redeye Growth Day.

CEO Martin Jönsson Presenting at Redeye Growth Day.

The use of PathHunter cell lines to discover modulators of Trk-receptors. From HTS to phase 1; Scientific presentation at the ELRIG Conference, Gothenburg, May 10-12, 2022.

AlzeCure – Alzheimer event at Redeye (Swedish).

Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease; Scientific presentation at the 2nd Swedish Meeting for Alzheimer Research, Stockholm.

Preliminary Results From a Single Ascending Dose Study in Healthy Volunteers of ACD856, a Positive Modulator of Neurotrophin Trk-Receptors; Scientific presentation at the 2nd Swedish Meeting for Alzheimer Research, Stockholm,

Identification of a positive modulator of neurotrophin recptors with memory-enhancing effects and improved mitochondrial function; Scientific presentation at the 2nd Swedish Meeting for Alzheimer Research.

A positive modulator of neurotrophin receptors improves cognition and mitochondrial function; Scientific presentation at the AD/PD conference, Barcelona, March 15-20, 2022.

NeuroRestore – Preliminary results from a Single Ascending Dose study in healthy volunteers of ACD856, a positive modulator of Neurotrophin Trk-receptors; Scientific presentation at the AD/PD conference, Barcelona, March 15-20, 2022

Watch the Analysisguide’s interview with AlzeCure’s CEO Martin Jönsson – about events in the company and the future (in Swedish).

CEO Martin Jönsson is interview by BioStock on the company’s latest developments, including the ongoing rights issue.

CSO Johan Sandin explains the science behind AlzeCure’s project portfolio and what distinguishes it from other pharma companies (Swedish).

See CEO Martin Jönsson and CSO Johan Sandin, present upcoming events in the company and the ongoing issue (Swedish).

Watch the interview with AlzeCure’s CEO Martin Jönsson – about events in the company and the ongoing issue (Swedish).

AlzeCure – New presentation at Penser (Swedish).

Latest newsflow (Swedish).

CEO Martin Jönsson presents at Aktiespararna (Swedish).

Alzstatin – Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease (Text only).

Alzstatin – Development of novel γ-secretase modulators for the treatment of Alzheimer’s disease.

Alzstatin – Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease, Scientific presentation at 11th Pharmaceutical Profiling meeting, January 27, 2022.

AlzeCure Pharma – Kapitalmarknadsdag.